Overview
Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter acetylcholine (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and surgical procedures. Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and lasting between four to six minutes, make succinylcholine particularly useful in the setting of short medical procedures requiring brief periods of muscle relaxation.
Indication
Succinylcholine is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/11/29 | Not Applicable | Not yet recruiting | Peng Liang | ||
2023/09/08 | Phase 4 | Recruiting | |||
2022/09/27 | Phase 4 | Completed | China-Japan Friendship Hospital | ||
2021/05/03 | Phase 4 | Completed | Matias Vested | ||
2020/10/09 | Phase 3 | Completed | |||
2018/05/22 | Phase 2 | Completed | |||
2018/03/19 | Not Applicable | UNKNOWN | |||
2016/09/26 | N/A | Completed | Jakob Louis Thomsen | ||
2016/07/04 | Phase 3 | Completed | Rennes University Hospital | ||
2016/02/05 | Phase 2 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Hikma Pharmaceuticals USA Inc. | 0143-9338 | INTRAMUSCULAR, INTRAVENOUS | 20 mg in 1 mL | 6/26/2023 | |
| Hikma Pharmaceuticals USA Inc. | 0641-6234 | INTRAMUSCULAR, INTRAVENOUS | 20 mg in 1 mL | 1/2/2024 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| ETHICHOLINE INJECTION 100 mg/2 ml | SIN05861P | INJECTION | 103 mg/2mL | 5/13/1991 | |
| MARTINDALE PHARMA SUXAMETHONIUM CHLORIDE SOLUTION FOR INJECTION 50MG/ML | SIN15643P | INJECTION, SOLUTION | 50MG/ML | 3/8/2019 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Suxamethonium Chloride Injection | 国药准字H20054746 | 化学药品 | 注射剂 | 6/5/2020 | |
| Suxamethonium Chloride Injection | 国药准字H11021581 | 化学药品 | 注射剂(小容量注射剂) | 7/23/2021 | |
| Suxamethonium Chloride Injection | 国药准字H20054745 | 化学药品 | 注射剂 | 6/5/2020 | |
| Suxamethonium Chloride Injection | 国药准字H31020599 | 化学药品 | 注射剂 | 7/22/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| SUXAMETHONIUM MEDSURGE suxamethonium chloride dihydrate 100 mg/2 mL solution for injection vial | 438912 | Medicine | A | 10/2/2024 | |
| SUXAMETHONIUM INTAS suxamethonium chloride dihydrate 100 mg/2 mL solution for injection pre-filled syringe | 330020 | Medicine | A | 8/26/2021 | |
| SUXAMETHONIUM ACCORD suxamethonium chloride dihydrate 100 mg/2 mL solution for injection pre-filled syringe | 330024 | Medicine | A | 8/26/2021 | |
| SUXAMETHONIUM JUNO suxamethonium chloride dihydrate 100 mg/2 mL injection ampoule | 320687 | Medicine | A | 1/17/2020 | |
| SUXAMETHONIUM MEDICIANZ suxamethonium chloride dihydrate 100 mg/2 mL solution for injection vial | 438911 | Medicine | A | 10/2/2024 |
Help Us Improve
Your feedback helps us provide better drug information and insights.